A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension
Korean patients aged 19 years or older diagnosed with hypertension
Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug
Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment
Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study
Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab.
Pregnant women, women who may be pregnant, and nursing mothers
Individuals currently participating in an interventional study
Individuals deemed unsuitable for participation in this study by the researcher for other reasons
General hospital
Cohort
Prospective
AMOPREL TAB 1.67/16.67/4.17mg
DrugFollow-up of subjects prescribed medication in a non-intervention study
The change in Systolic Blood Pressure (SBP) relative to baseline
effectiveness of sequential triple combination therapy (amlodipine/losartan/chlorthalidone)
Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at 2 and 4 months, and change from baseline in DBP at 6 months
Prescription patterns of a triple-therapy-based stepwise treatment strategy
Proportion of Participants by Study Drug Dosage at Months 2, 4, and 6
safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone)
Incidence of Adverse Events During the 6-Month Follow-up Period
Click on the lead sponsor to view all of their trials.